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Due to intensiﬁed research in recent years, the understanding of the molecular mechanisms involved in the development of
melanoma has dramatically improved. The discovery of speciﬁc, causal mutations such as BRAF or KIT oncogenes not only
r e n d e r sat a r g e t e da n dt h u sm o r ee ﬀective therapeutic approach possible, but also gives rise to a new genetic-based classiﬁcation.
Targeting just a few out of several potential mutations, BRAF-Inhibitors such as PLX4032 achieved already tremendous results in
the therapy of metastatic melanoma. Up to now, the correlation of clinical, histomorphologic, and genetic features is, however,
not understood. Even more, is it not well known precisely what kind of molecular changes predispose the primary melanoma
for metastasis. The identiﬁcation of morphological surrogates and prognostic parameters in tumors with such genetic alteration
seems therefore crucial when diﬀerentiating and classifying this heterogeneous tumor entity in more detail and thus facilitates
the stratiﬁcation of prognosis as well as therapy. This review summarizes the current understanding of carcinogenesis and gives a
detailed overview of known morphologic and potentially future genetic prognostic parameters in malignant melanoma.
1.Introduction
Despite all preventive and therapeutical eﬀorts, melanoma is
still the most aggressive and deadliest skin cancer especially
in persons of fair complexion. To a certain extent, primary
prevention campaigns already achieved an earlier diagnosis
of thinner tumors with a better prognosis [1]. Incidence
rates are nonetheless increasing worldwide mainly due to
unreasonable sun exposure habits, especially in young adults
[2]. Once diagnosed, prognosis and therapy is stratiﬁed so
far by several clinicopathological risk factors such as tumor
thickness, sentinel lymph node status, ulceration, and the
recently added mitotic rate [3]. In view of an often unpre-
dictable rather heterogeneous biological behavior mainly
in >4mm thick (Stage IIC) or locally advanced melanoma
(Stage III), the AJCC classiﬁcation remains of limited
clinical relevance in particular for these high risk patients
[4]. Moreover, we currently do not have reliable tissue
biomarkers that mark the disease of the individual patient
for progression or complete remission [5]. At the same time,
an enormous amount of basic research within the last decade
has dramatically changed the molecular understanding of
melanoma. Proof of several speciﬁc genomic key mutations
such that BRAF could not only be causally linked to disease
progression [6] but also gave rise to new, highly eﬀective
therapies targeted speciﬁcally at those mutated molecules
[7]. While the multistep carcinogenesis of melanoma is still
too little understood in its complexity in order to foresee
when, how, and what kind of mutation develops in an
invasive or metastatic tumor, genome-wide genetic analysis
of primary or metastatic tumors will undoubtedly change
future classiﬁcations and subsequent treatment algorithms.
But are standard clinical prognostic parameters such
as age, location, and metastasis already outdated? Could
dermatopathology, the current cost-eﬃcient diagnostic gold
standard, consequently be redundant? Will we possibly be
abletocorrelatecertainhistomorphologicfeaturestospeciﬁc
genetic aberrations and their consecutive pathological or2 Journal of Skin Cancer
compensatory molecular cascades in order to recognize,
treat, or even prevent the systemic metastasic impact of
this tumor in our patients? These important questions arise
and may contribute to a better classiﬁcation of melanoma
patients. With the focus on their metastatic potential, our
review summarizes the current knowledge of genetic, as well
as molecular features of malignant melanoma and examines
their possible correlation. Moreover, we discuss the clinical
implicationsaswellascurrenttherapiesthatmaytargetthese
new hallmarks of melanoma.
2. Epidemiology of Malignant Melanoma
Agrowingbodyofevidencehasalreadyaddressedmelanoma
as an “umbrella term” for several biological distinct subtypes
asaresultofmultiple causativegeneticaberrations,impaired
pathways, or epigenetic changes. Epidemiology, in contrast,
strongly indicates that UV-induced DNA damage is the
primary cause of melanoma development [8], even though
certain regions in which melanoma subtypes occur, such
as mucosal or acral tumours, are not typically exposed to
ultraviolet light. Numerous studies about phenotypic risks
such as age, gender, and skin type favour sun exposure as the
major cause for thinner tumors of less incidence in young
patients (<35 years) on minimally exposed sites and thicker
tumours in elderly patients and UV-exposed locations such
as the head and neck [9, 10]. Searching for the underlying
causes of initiation and progression in these melanomas,
it was demonstrated that cyclobutane pyrimidine dimers
(CPD) and pyrimidine-pyrimidone (PP) photoproducts are
themostabundantDNAlesionsinthoseUV-exposedtumors
[11]. A well-determined repair system of minimal necessary
f a c t o r ss u c ha sX P A ,R P A ,X P C ,a n ds of o r t h ,i s ,h o w e v e r ,
suﬃcient to remove those photoproducts from DNA [12].
Although there is clear evidence linking a deﬁcient repair
system in Xeroderma pigmentosum to a higher susceptibility
of cutaneous melanoma, a presumably impaired altered
expression of repair genes may also contribute to the devel-
opment of melanoma but was thus far not detected [13, 14].
On the contrary, as recently shown by Gaddameedhi et al.,
melanoma cell lines and melanocytes have displayed an
equally eﬃcient DNA repair system in primary tumours as
well as in metastasis [15]. Even in NRAS or BRAF mutant
melanomas, no reduced function or expression of the DNA
repair system could be found [15]. p53 mutations are only
found in 1% of primary melanomas and only 5% of metas-
tasis. Nonetheless, it was suggested that the p53-mediated
repair system and well as other aberrations such as MCR1,
MITF, or CDKN2A inﬂuence UV-induced expression of this
potenttumoursuppressor.However,itisstillnotknownhow
thediﬀerentp53functionsultimatelymanipulatethecellfate
in melanoma [15, 16]. Recent numerous molecular genetic
studies, strongly support that melanomas of the trunk of
younger patients with multiple nevi diﬀer enormously from
thoseinelderlypatientswithcumulativelysun-damagedskin
[17, 18]. Despite the evidence for causal factors such as age,
phenotype, pattern, and dose of sun exposure, the underly-
ing genetic propensities in subentities such as desmoplastic
melanoma, uvea melanoma, or melanoma in childhood are
not really understood. Genome-wide studies will, however,
help to identify these constitutional factors as likely heritable
contributors to melanoma risk and to propose possible new
target-oriented therapies in the future [19].
3.Clinicopathological Parametersin
MalignantMelanoma
Measurable diagnostic prognostic indicators and prognostic
biomarkers are needed to reﬁne the risk and assess the out-
come in patients with malignant melanoma. As much eﬀort
as has been made by the AJCC in identifying reliable risk
factors, the current classiﬁcation still allows only a limited
stratiﬁcation of this rather heterogeneous tumour [4]. Apart
from the classic clinical adverse parameters such as gender,
age, location, and metastasis, histopathological parameters
includedsofarareBreslowthickness,ClarkLevel,ulceration,
sentinel status, and the recently added mitotic rate [3]. Yet,
the new forthcoming genetic features of primary tumours,
for example, the BRAF or KIT mutation, are not taken into
account up to now within the classiﬁcations but certainly
merit reﬂection in the future. Although their consideration
would certainly be premature, several approaches already
propose to integrate those molecular markers and thereby
reﬁne distinct subcategories of malignant melanoma [18, 20,
21]. In order to identify homogeneous disease groups in
greater detail and implement an improved patient manage-
ment, phenotypic consequences of those genetic alterations
must be better understood [22]. But in virtually all well-
established, time-tested, clinicohistopathological standard
factors, the underlying biological mechanisms are, as shown
below, completely unknown.
3.1. Breslow’s Thickness. First introduced by Breslow in 1970
and later named after him, “Breslow thickness” is the eldest
andoneofthemostimportanttissuebiomarkersoftheAJCC
classiﬁcation [23]. In association with horizontal enlarge-
ment, it was originally viewed and, thereafter, rectiﬁed as a
parameter of tumour burden. Breslow’s thickness nonethe-
less accurately predicts the risk of lymph node metastasis,
with deeper tumours being more likely to involve the nodes
[24]. Compared to Breslow’s depth, Clark’s level which
describes the depth of tumoral penetration according to
the anatomical skin layer (epidermis, dermis, and subcutis)
h a sb e e np r o v e nt ob el e s sr e p r o d u c i b l e ,m o r eo p e r a t o r
dependent, and of lower predictive value [25]. Its prognostic
signiﬁcance has, therefore, been limited to patients with very
thin tumors in the current AJCC staging system [3]. The
biological relevance of Breslow’s depth’s is, however, still
almost unknown. Several potential molecular contributors
to proliferation and, therefore, tumor thickness are currently
under investigation. In particular, basic ﬁbroblast growth
factor (bFGF) is characterized as a highly mitogenic factor
in melanoma especially when combined with UV [26] FGF
receptor 4 (FGFR4) and its Arg388 genotype [27], cell
cycle regulator proteins, or genes such as p53 and others
[28, 29]a sw e l la sB c l - 2o n c o p r o t e i n[ 28], cell adhesionJournal of Skin Cancer 3
defects, or cell-cell signaling mutations [29]h a v ep r o v e nt o
be correlated with increased tumor thickness. Especially for
the FGFR4Arg388 allele, there was convincing evidence of
intensiﬁed cell motility and invasiveness [30, 31] but also
increased vertical growth and risk of metastasis in nodular
and superﬁcial spreading melanoma [27]. Even though no
correlation between decreased survival rate and outcome
could so far be provided and the precise mechanism is not
understood, FGFR4 Arg388 polymorphism predicts a more
aggressive phenotype in terms of progression in melanoma
as well as breast cancer [27, 31]. As the largest genomic
structure in the FGFR family, loss-of-function mutations in
FGFR2 have lately also been shown to occur in subsets of
melanomas [32]. Neither mutations in FGFR4 nor in FGFR2
as a possible contribution to an inherited predisposition to
skin cancer, could, however, be detected in healthy caucasian
women [33]. Genetic variants of FGFR4 and FGFR2 seem,
therefore,tofunctionaspotentialbiomarkersforprogression
rather than as a risk factor of skin cancer development [33].
3.2. Ulceration. In contrast to an ulcer due to trauma, ul-
ceration in melanoma is deﬁned as “a consumption of
the epidermis” with a thinned epidermis to the side of
the defect [34]. Initially identiﬁed as an adverse prognostic
parameter by Allen and Spitz in 1953 [35], subsequently
validated by Balch et al. [36], and later on by numerous
other studies [37–39], ulceration has been convincingly
shown to be an independent predictor of sentinel status and
overall survival even in high-risk thick melanomas >4mm
[40, 41]. Despite its inclusion in the AJCC classiﬁcation
already in 2001 [42], the knowledge about why, when,
and for what reason ulceration occurs and how it favours
tumorprogressionisatbesttheoretical.Studiesconcentrated
on width [36], depth [43], and proportion of ulceration
[44], its association with mitotic rate [45] or vascular
involvement, and tumor vascularity [46]. The results were,
however, often inconclusive. The most plausible hypothesis
that considered ulceration as a consequence of tumor
proliferation, and therefore secondary epidermal thinning
and contact ulceration, has been reevaluated. A recent study
has demonstrated an independent prognostic association of
ulceration and mitotic activity [47]. In addition, a direct
inﬂuence on the local tumor environment seems nonetheless
possible. Hence, ulceration challenges the control functions
of keratinocytes, melanoma cells are enabled to transform
more easily, therefore favoring tumor progression [48].
3.3. Regression. M o r ec o m m o ni nm e l a n o m at h a ni na n y
otherneoplasia[49],regressionisdeﬁnedasapartialorcom-
plete disappearance of the tumor without treatment [50].
Due to the loss in pigmentation in terms of a blue or grey-
whitish discoloration, it is clinically highly apparent in this
particular tumor entity. With an incidence of approximately
10–35% of patients with primary malignant melanoma [51],
regression arises speciﬁcally in thinner tumors but hardly
ever in nodular melanoma [52]. Associated with variable
degrees of inﬂammatory and stromal changes, this partic-
ular phenomenon proceeds from an early dense lichenoid
inﬁltrate of lymphocytes and dermal edema to a late ﬁbrosis
and a usual melanosis within a thickened papillary dermis
[53].Especiallywhenthetumorispigmented,melanophages
as the histopathological telltale sign are often present.
Although the current understanding of regression is clearly
that of an immune-mediated, cancer-autonomous process
[21], neither its biological signiﬁcance nor the underlying
molecular or genomic aberrations are so far recognized.
Possible explanations vary from an increased T-cell response
[54], an inhibited angiogenesis [53], to a forced apoptosis of
tumor cells [53, 55]. Consequently there are diﬀerent ther-
apeutical implications of regression. While a positive host
immune response may supersede wider excision margins or
sentinel lymph node biopsy [56, 57], regression may, how-
ever, on the other side indicate a formerly deeper inﬁltrating
tumor and thus a lower threshold for sentinel lymph node
biopsy[58].Especiallyinthinmelanomas<1mm,regression
as a left-over of a presumably thicker tumor therefore still
leads to wider surgical margins and a lower threshold for
SLN biopsy [58]. The most convincing, although unproven,
hypotheses for a regression-driven tumor progression so far
aretheHammon’seﬀect,whichpostulatesanaturalselection
of aggressive residual tumor clones as a result of regression
[59, 60] and Bastian’s telomere crisis, which argues that a
massive senescence and cellular apoptosis equally favor the
selection of genomic aberrations and therefore progression
[55]. Future epidemiologic studies investigating the impact
of regression of the primary tumor for the prognosis of
melanoma are certainly required to further investigate those
intriguing details.
3.4. Mitotic Rate. Tumor proliferation as deﬁned by mitotic
rate has been conﬁrmed as an independent adverse prognos-
tic parameter in many solid neoplasia including melanoma
[61–64]. Due to the fact that its increase is signiﬁcantly
correlated with reduced survival rates primarily within
melanoma of less than 1mm tumor thickness, it has recently
replaced Clark’s level as the primary criteria for deﬁning the
subcategory of T1b in AJCC classiﬁcation 2009 [3, 65]. The
lack of a universally agreed approach of how to document
mitotic ﬁgures led to many studies that did not include
mitotic rate in their analyses up to now [66]. As recently
detailed by the AJCC manual, starting with dermal areas that
contain most mitoses (so-called hot spots), and extending
the approach later to adjacent ﬁelds up to 1mm2,n o wa l l o w s
for the ﬁrst time a reproducible assessment [3] although
this approach is time consuming to the dermatopathologist.
So far, only two sorts of genes and their pathways are
identiﬁed to be overrepresented in melanoma with higher
mitotic activity. Replication Origins Firing (ROF) genes such
as MCM4 and MCM6 as well as the oncogene securin are
strongly correlated with metastases and therefore poorer
prognosis even after considering other prognostic parame-
ters such as sex, age, location of the primary, thickness, and
ulceration[29,67].Asmucheﬀorthasbeenmadeindeﬁning
the biological relevance of these dermatohistopathological
parameters, they cannot reliably distinguish the metastatic
behaviour of certain subgroups such as Stage IIC melanoma.4 Journal of Skin Cancer
Moreover, the exact diagnosis in some cases of melanoma
might be problematic altogether as the individual assessment
of these criteria diﬀers among pathologists [68]. In addition,
benign melanocytic proliferations such as atypical nevi can
also display a number of those features, given that routinely
performed immunohistochemical markers, for example,
S100B and HMB-45 are of little help in distinguishing nevi
from melanoma [69]. Taken these reﬂections into account, a
moremolecularunderstandingofmelanomamighttherefore
be desirable. Inevitably, the understanding of the molecular
basis of malignant melanoma has to be further improved
to identify the critical “drivers” and “passengers” during
oncogenesis of melanoma [70, 71].
4. CurrentKnowledge about Oncogenesis of
MalignantMelanoma
The core issue obscuring the best possible treatment
of malignant melanoma is still its unpredictable pattern
of progression and metastasis. Well-established prognostic
parameters alone or in combination are so far not eﬀective
enough to accurately predict the outcome for every indi-
vidual patient. Biologically distinct as malignant melanoma
is, the greatest therapeutical potential lies without doubt
in the understanding of what key indicators inﬂuence the
course of the disease most, regardless whether they may
be genetic, possibly molecular, least likely clinical, or even
combined, and therefore predispose for the risk of systemic
disease.Themultistepprocessofcarcinogenesisinmalignant
melanoma is, however, complex and at best only in part
understood.Anumberofexcellentreviewshavesummarized
theexcitingdevelopmentsintheunderstandingofthistumor
in depth [72]. To date, four pivotal, nonlinear, and rather
netlike interwoven defective signaling pathways have been
implicated. These are MAP kinase, PI3K/AKT, MITF, and
WNT. The following scheme gives a simpliﬁed overview of
these pathways with their most common aberration and
the percentage of mutations detected within these signaling
pathways.Certainraresubtypessuchasuvealmelanomaalso
have been found to have mutations in GNAQ [73]o rG N A 1 1
[74]thatalsoleadtoconstitutiveactivationofthesesignaling
pathways (Figure 1).
Proventobeoneofthemostfrequentlymutatedcascades
in melanoma, the mitogen-activated protein (MAP) kinase
pathway shows several pathologically activated mutations
that may contribute to malignant transformation. The most
common mutations or cytogenetic ampliﬁcations occur in
the BRAF, the KIT, the NRAS, or the CDKN2A genes. In 8–
12% of familiar malignant melanoma alone, mutations of
CDKN2A gene that are linked to chromosome 9p21 arise
[75, 76].
Unlike regular sites of cutaneous melanoma, uncommon
subsets of melanocytic neoplasia such as uveal melanoma or
malignant blue nevus lack frequent oncogenetic mutations
in cKIT, NRAS, or BRAF [77–79]. Notwithstanding other
oncogenes such as the alpha subunit of a class of heter-
otrimeric GTP-binding proteins (Gq), namely GNAQ and
GNA11, are activated. Hypermorphic mutations in those
genes were found to contribute to skin darkening and
therefore melanocyte biology in mice [80]. Proven to occur
early in progression, they seem, however, not to be related
to clinical outcome so far [81, 82]. When active, GNAQ
andGNA11alternativelyupregulatetheMAPkinasepathway
[73]. Operating downstream of several G-protein coupled
receptors, GNA11 has presumably a more potent adverse
eﬀect than GNAQ in locally advanced or metastasized
tumors although overall survival did not diﬀer [74]. GNAQ
mutations are, however, considered to be more sensitive to
the upcoming therapeutical MEK inhibition [73].
Cross-linked via NRAS, the MAP kinase cascade also
initiates the PI3K and thereby the PI3K signaling pathway,
another defective cascade found in a large percentage of
melanomas. Apart from NRAS, either deletion of PTEN or
overexpression of AKT mainly lead to the stimulation of
mTOR, a central regulator of cell growth and proliferation
that has raised substantial interest in this signaling pathway
in melanoma [83].
Of central importance for benign as well as malignant
melanocytes, MITF and its cascade were found to represent
a central transcription factor that regulates diﬀerentiation
in the pigment cell system [84]. In addition to α-MSH
and ACTH that activate MITF via the MC1R, it is also
physiologically regulated by MAP kinase and PI3K signaling
pathway[85,86].Inthedevelopmentofmelanoma,however,
an optimized level of MITF as an oncogene for proliferation
and survival of tumor cells needs to be maintained by BRAF
[87]. Insuﬃciently high or low expression of MITF results
in tumor-protective diﬀerentiation, cell cycle arrest, and
subsequent apoptosis [88]. MITF ampliﬁcation, single based
MITF substitution and even mutation of its regulator SOX10
have all been proven lately to be causative for altered MITF
function in both primary and metastatic melanoma [89, 90]
underscoring the involvement of MITF in melanomagenesis.
Although mutations of the β-catenin gene and APC
have already been detected, the WNT signaling pathway has
not been extensively implicated in melanoma development
this far, due to the fact that defective β-catenin is rarely
identiﬁed although it clearly acts as a melanoma-speciﬁc
antigen [91, 92]. Under physiological conditions, WNT-
signaling proteins bind to Frizzeled receptors, thereby stabi-
lizing β-catenin with subsequent release from a multiprotein
complex. It then accumulates in the nucleus and initiates
as a coactivator the transcription of a multitude of target
genes. In case of genetic mutations of β-catenin, such as
in malignant melanoma, it forms a complex with LEF-
1 (lymphoid enhancer-binding protein), which in turn
leads to malignant transformation of the cell [93, 94]. In
particular Wnt-2, a survival factor in human carcinogenesis,
[95]h a sl a t e l yb e c o m ef o c u so fi n t e n s i ﬁ e dr e s e a r c ha sa
biomarker and a potential target to subclassify and treat
malignant melanoma [96, 97]. Besides the main canoni-
cal WNT signaling pathway, a variation of the so-called
noncanonical pathway with altered receptors and enzymes,
and even a signal regulated in a paracrine manner (the so-
called “notch” cascade), diversify and complicate the WNT
signaling pathway considerably [98]. Speciﬁc inhibitors in
terms of small molecular antagonists or RNA aptamersJournal of Skin Cancer 5
Receptor tyrosine kinase
MITF
PKA
GNAQ/GNA11
CREB
MITF
ERK
MEK
BRAF NRAS
20%
PI3K/AKT WNT
60%
60%
90%
MAP-kinase
C-KIT
0–39%
10–20%
Progression
Induction Inhibition
DNA damage Anti-apoptosis Growth, metastasis Proliferation
WNT
15–60%
GNA11
GNAQ
CCND1
CDKN2A
CDK4/6 p16
PTEN
PI3K
AKT
mTor
Bcl-2, Bcl-xL, Mcl-1
p53
NOXA, PUMA,
BIM, BID, BAD
BAK
BAX
α-MSH
β-catenin
β-catenin
Figure 1: Signaling pathways in malignant melanoma (modiﬁed according to http://www.cancercommons.org/).
have nonetheless been developed to potentially target this
pathway, an intruiging possibility given the important role
of this pathway in the so-called “tumor-initiating cells” in
other tumor entities [99]. WNT2 has also been found to be
overexpressed in malignant melanoma [97]. Of therapeutic
interest, a speciﬁc anti-WNT-2 monoclonal antibody has
been proven to inhibit WNT signaling and subsequently
induce apoptosis [96].
The complexity of these crosstalking circuits is increased
even more by the fact that one genetic alteration is not
enough to make a melanoma. Several additional changes
are needed in a multistep process to result in malignant
transformation [100]. Cumulative genetic instability grad-
ually induces arbitrary genomic aberrations that lead to
uncontrolledreplicationandgrowth,inhibitionofapoptosis,
and ﬁnally the ability to invade and metastasize due to a
Darwinian-like selection process of the tumor cells [101–
103]. Considering further stem cell-determined, epigenetic,
tumor-environmental, or immunologic changes, the variety
of possible inﬂuencing factors on the classic hallmarks
of cancer is multiplied beyond measure [104], and the
knowledge of critical constitutional and somatic genetic
parameters is not yet complete [22].
5.Epigenetics
Recent progress in the understanding of genetic aberrations
in malignant melanoma has likewise prompted signiﬁcant
eﬀorts in deﬁning so called “epigenetic” changes that
accompany the malignant transformation in melanocytes.
Deﬁned as any changes in gene expression that are not
achieved through alterations in the primary sequence of
the genomic DNA, epigenetics inﬂuence a wide range of
alternative gene functions such as cell cycle regulation, cell
signaling, diﬀerentiation, DNA repair, apoptosis, invasion,
metastasis, angiogenesis, and immune recognition [105].
Although their precise contribution to tumor progression
is still unknown, they were proven to eﬃciently restore
the expression of aberrantly silenced genes and thereby
to reestablish silenced signaling pathway function [106].
The most clearly identiﬁed epigenetic mediators so far are
the methylation of DNA in the context of CpG dinu-
cleotides, the posttranslational changes of histone proteins
and, though less characterized, the inﬂuence of microRNAs
(miRNAs).Thereactivationof“sleeper” genesandthemain-
tenance of these epigenetics aberrations requires functioning
enzymes such as DNA methyltransferases (DNMT) or his-
tone deacetylases (HDAC), and histone methyl transferases
(HMT), respectively. In case of DNA methylation, three
diﬀerent DNMTs are implicated in new methylation patterns
with gene-speciﬁc hypermethylation on the one hand as
well as genome-wide hypomethylation on the other [107].
In addition to genetic alterations, epigenetic DNA hyper-
methylation is, therefore, a complementary, frequent, and
important mechanism to inactivate tumor suppressor genes
such as CDKN2A [108]. While hypermethylation silences
tumor suppressor genes, global hypomethylation might,
however, activate the expression of oncogenes. This could
lead to a diversiﬁed and signiﬁcantly impaired methylation
disbalanceofmultiplegenesthateventuallyinitiatesgenomic6 Journal of Skin Cancer
instability, tumorigenesis, and cancerprogression [106,107].
As common as this phenomenon of hypomethylation is
in many tumors, little is known so far about target genes
regulated by this event in melanoma [109]. Similar to the
discussion of driver and passenger mutations in genetic
aberrations, the biological signiﬁcance of several identiﬁed
aberrantly hypomethylated epigenetic genes, for example,
cancer-testis antigen (CTAs), PRAME, and MAGE continue
to be poorly understood. Nonetheless, given the broad
relevance of these pathways in almost every tumor entity,
substances have already been developed for therapeutical
approaches, and the epigenetic status of certain genes may
potentially predict the biological function and could serve as
ab i o m a r k e r[ 110, 111].
Along with DNA methylation patterns, initial studies
about histone acetylation have addressed a possible role in
melanoma development and progression [112]. In particular
hypoacetylation-mediateddownregulationofCDKN1Aand,
similarly, proapoptotic proteins such as BAX, BAK, BID,
and BIM may profoundly inﬂuence cell cycle and apop-
tosis of the cell and thereby lead to tumor progression
or therapeutic resistance [113, 114]. In the demanding
packing and outpacking machinery of genomic DNA into
nucleosomes and chromatine, respectively, at least three
groups of histone acetyltransferases (HAT) and 18 iden-
tiﬁed histone deacetylases (HDAC) are involved thus far
[115]. Complicating this picture, histone methyl transferases
(HMTs) modulate the chromatin compaction grade of the
DNA that ﬁnally determines the transcriptional status of
target genes [116]. In contrast to DNA methylation, the
knowledge of the posttranslational aberration of histones is
altogetherscarceandmainlygatheredindirectlybytreatment
results of HDACs thus far. Promising results of multiple
HDAC inhibitors concerning vascular endothelial growth
factor (VEGF), generation of reactive oxygen species (ROS),
cell death, senescence, and especially intrinsic as well as
extrinsic apoptosis in the transformed cells have already
been described in various solid tumor entities [117–119].
Proapoptotic stimuli are, however, known to be less eﬀective
in human melanoma cell lines. Recently discovered key
mediators such as the cleavage of Poly-ADP ribose protein
(PARP) [113] and HDAC inhibitors like the short fatty
acid VPA [120] have led already to promising results with
antitumor activity in combination therapy with anthra-
cyclines in melanoma [121]. The level of understanding
of the molecular mechanism in histone posttranslational
modiﬁcations has yet to become more reﬁned to predict
the outcome of such promising therapies in subgroups or
individual melanoma patients.
The most recently discovered players in epigenetic reg-
ulation have been noncoding microRNA (miRNA). Once
transcribed in the nucleus and further processed by several
intermediate stages, they are ﬁnally incorporated into a
RNA-induced silencing complex that recognizes their tar-
get miRNA. This either inhibits their translation or (less
frequent) causes their degradation [122]. Each miRNA has
several target RNAs and vice versa. In addition to more than
a hundred currently conﬁrmed miRNAs, more than 1000
miRNAhavebeenpredictedbybioinformatics[123].Despite
the limited data available so far, miRNAs are proven to play
pivotal roles in the epigenetic pathogenesis of human cancer.
As proof of principle, several key miRNAs have already
been identiﬁed in driving tumorigenesis and progression
in malignant melanoma [124]. Especially the lack of an
inhibition by miR-137 and miR-182 was found to result in
an overexpression of MITF, a master regulator in benign
m e l a n o c y t e sa sw e l la sm e l a n o m a[ 124]. On the other
hand, overexpression of miR-182 contributes likewise to
progression and metastasis by repressing MITF [124]. In
a similar way, miR-34b, miR34c, miR199a, and miRNAs
involved in the expression of the oncogene MET modify
target gene expression in accordance with the stage of
cancerdevelopment[125].ConsideringthefactthatmiRNAs
themselves are also targets of epigenetic regulations as, for
example, miR-34a, which is proven to be silenced by a CpG-
mediated methylation in up to 60% of primary melanomas
[126], further studies are mandatory to deﬁne their role in
melanoma biology more precisely.
6. Oncogene-Deﬁned Targeted Therapy in
the Era of BRAF Inhibitors
As one of the most devastating forms of cancer in terms
of life expectancy and outcome, metastatic melanoma was
until recently an almost intractable disease. This was largely
explained by the fact that mono- or polychemotherapy, the
standard of care for over 30 years, only beneﬁts a very small
subset of patients. With the discovery of an activating muta-
tion of BRAF in 50–60% of all melanoma, with 90% of these
tumors carrying a substitution at V600, a ﬁrst tumor-speciﬁc
target for a treatment was identiﬁed in 2002 [6]. Sorafenib, a
multikinase inhibitor and one of the ﬁrst targeted therapies
in clinical testing, has unfortunately shown little eﬃcacy in
patients with activated MAP kinase pathway (and therefore
BRAF positive) patients [127]. Consequently, more selective
BRAF inhibitors were subsequently tested in clinical trials,
which in case of vemurafenib (also known as PLX 4032)
and GSK2118436 have demonstrated unprecedented clinical
results in metastatic malignant melanoma harboring BRAF
mutation [7, 128, 129]. Within two weeks, the majority of
patients stated a symptomatic improvement, and approx-
imately 60% showed an objective response according to
response evalutation criteria in solid tumors (RECISTs).
Overall about 80% of all patients with metastatic tumors
experienced somedegree of regression [7]. In the subsequent
extension phase of the trial, 81% patients demonstrated
tumor regression, and the progression-free survival was at
an average of 7 months [7]. Dose-dependant adverse events
like rash, photosensitivity, fatigue, and arthralgia were well
managed by either dose reduction or by the termination of
the treatment if necessary. GSK2118436 has proven to be
even of higher potency at a lower concentration [129]. Apart
from pyrexia, rash, fatigue, headache, nausea, and vomiting,
s e v e r ea d v e r s ee v e n t ss u c ha ss q u a m o u sc e l lc a r c i n o m aa n d
keratoacanthoma were reported. A series of publications,
however,quicklydiscoverednovelmechanismsthatparadox-
ically activate the MAP kinase pathway in the presence ofJournal of Skin Cancer 7
Table 1: Genetic mutations and corresponding current and future
targeted therapies.
Pathway Target Therapy
MAP-kinase
Receptor tyrosine
kinase
Imatinib
Dasatinib
Nilotinib
Masitinib
BRAF GSK2118436
Vemurafenib
NRAS Sorafenib
Tipifamib
CRAS Lonafamib
RAF265
PI3AK
mTor
Sirolimus
Temsirolimus
Everolimus
PI3, AKT
GDC0941,
GSK2126458,
BEZ235,
BKM120,
XL765,
MK2206,
GSK 690693
MITF CDK2, HDAC SCH727965,
panobinostat
WNT B catenin
Small
molecular
antagonists
RNA
aptamers
BRAF inhibitors [130, 131]. Due to three isoenzymes of RAF
(A-RAF, B-RAF, and C-RAF), the inhibition of one of them
such as B-RAF can induce a compensatory transactivation
of C-RAF, which in turn activates downstream MEK and
the subsequent pathway [130, 132]. As a consequence of
“gatekeeper” mutations that sterically prevent the inhibitor
binding to the active side in RAF, the crossactivation of C-
RAF is not always initiated and even to a certain extent
inhibitedbythegivendrug[132].ATPcompetitiveinhibitors
for instance are supposed to stabilize the interaction between
B-RAF and C-RAF [133]. Besides C-RAF as a paradoxical
bypass of B-RAF, other ERK-dependent mechanisms such as
N-RAS mutation, COX overexpression, or MEK1 mutations
contribute to an acquired resistance to B-RAF [134]. Com-
plicating the picture, even ERK-independent alterations like
PDGFRβ overexpression, IGF1R activation and PTEN loss
have been identiﬁed to reactivate ERK signaling in B-RAF
mutant tumors [134, 135]. Although the beneﬁt of B-RAF
inhibition as monotherapy has been suﬃciently conﬁrmed,
rapidlyoccuringsecondaryresistancemechanismsintumors
will most likely favor combination therapies targeting other
genetic “hot spots” in melanoma such as MEK, RAS, and
KIT.
RAS, in particular N-RAS mutations, occur in approx-
imately 15–25% of malignant melanoma. They inhibit the
G T P a s e - m e d i a t e da c t i v i t yo fR A Sa n dt h u sk e e pi ti n
an continuously active state [136]. Demanding as task to
develop an agent is that would rival GTP, several interacting
pathways such as MAP kinase or PI3 kinase seem to play an
important role in the N-RAS mutant subset of melanoma
[137, 138]. Mutually exclusive to B-RAF V600E mutation
[136], NRAS mutations have been shown to be sensitive
to MEK-targeted therapies particularly in combination with
PI3K, AKT, or mTOR inhibitors [137].
KIT mutations have so far been found in a small sub-
group of melanomas, in particular acral or mucosal tumors
that are not related to sun exposure [20]. According to
the results in gastrointestinal stroma tumors (GISTs), KIT
inhibitors such as imatinib and sunitinib, and newer in-
hibitors such as nilotinib or dasatinib have been described,
however,tobelessresponsive[139,140].Encouragingtothis
subgroupofpatients,anecdotalreportshaveshowncomplete
remission lasting up to one year [141].
Despiteseveralpromisingnewagents(Table 1),thereare,
however, still no therapeutic strategies that would reliably
conquer the complexity of pathways resulting in a highly
aggressive malignancy in melanoma. Considering several
multimarker assays using in vivo samples and cell culture
of primary melanomas and metastasis together, melanoma
development itemizes to several hundreds of involved genes
that seem too plentiful to be individualized for a targeted
therapy in a single patient, even though new, potentially
essential,markergeneshavebeenidentiﬁedandarecurrently
tested [142]. The very view of resistance, unwanted side
eﬀects, and rapid progression after initial responsiveness
clearly emphasize the importance of a thorough, genotypical
stratiﬁcation, and a “driver-focused” synergistic therapy. The
development of an oncogene hierarchy with diﬀerentiation
into important drivers and bystanding passengers seems
therefore necessary.
7. Conclusion
The recently gained knowledge about the functional impor-
tance of muted genes in a high proportion of malignant
melanoma has fundamentally changed the diagnostic and
therapeutic approach. In view of the focus on BRAF, NRAS,
KIT, and PTEN, four key genomic defective alterations and
their corresponding pathways are identiﬁed that without any
doubt reﬁne and extend the understanding of its bewildering
biological complexity. Although an improved classiﬁcation
[4, 18, 22] and corresponding risk stratiﬁcations and target-
oriented therapies (Table 1)a r ew i t h i nr e a c h ,o ri nc a s eo f
the latter even under eﬀective investigation, a restriction to
some precious few control factors seems to be a too easy
answer. The serious question remains, how do the highly
relevant histopathological parameters translate in a beneﬁt
for distinct subsets of the melanoma patients?
The answer probably lies in the identiﬁcation of the
biological “Achilles heel” of individual tumors. As convinc-
ingly shown, molecular analysis of subsets of melanoma has8 Journal of Skin Cancer
at ﬁrst revealed mutations in cKIT. This knowledge was
then rapidly translated into a successful targeted therapy
[18]. Other positive examples are the more recent successful
translation of the knowledge of the BRAF mutational status
(e.g., V600E) into elegant mutation speciﬁc, and at least
short-term successful therapy in these patients [7]. However
it is not surprising that in a large number of melanoma
patients such single mutations do not precisely delineate the
biological behaviour of the tumor at the time of primary
melanoma diagnosis. In fact, there appear to be a multitude
of biologically distinct melanoma entities. Thus, it is likely
that this straightforward approach is too narrow, given that
in a considerable fraction of melanomas so far unknown
oncogenes or tumor suppressors, or combinations thereof
may control tumor cell fate [143]. Most likely unbiased
approaches to melanoma using 21st century technology
of genetic proﬁling will yield intriguing results [144]. As
much as the classic hallmarks of cancer withstood the test
of time [102]: recently discovered characteristics such as
antiapoptotic parameters [145], the role of tumor stem
cells [146], telomerases [147], or circulating tumor cells
[148], as well as other tumor-environmental and epigenetic
phenomena[106,115]havealsotobetakenintoaccountand
may translate into successful therapy [104]. But hopefully,
as Hanahan and Weinberg lately stated, this phenotypic
myriad in melanoma [19, 149]m a yp o r t r a yj u s taf e w
of the causal principles of distinct tumor cell types that
need to be clariﬁed in order to improve the treatment and
outcome in our melanoma patients [104]. So, in the era of
molecular proﬁling, the gist of the matter “what’s really risky
in melanoma” seems within reach.
List of Abbreviations to Figure1
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